Ventricular reverse remodeling and 6-month outcomes in patients receiving cardiac resynchronization therapy: analysis of the MIRACLE study.
OBJECTIVE
The objective of this analysis was to determine if there were differences in ventricular reverse remodeling and 6-month outcome with cardiac resynchronization therapy (CRT) among specific subgroups enrolled in the Multicenter InSync Randomized Clinical Evaluation (MIRACLE) Study.


BACKGROUND
Analysis of major subgroups receiving CRT is important in determining who may be most likely to benefit, since all patients who receive CRT do not demonstrate improvement.


METHODS
Differences in response to CRT between subgroups based on baseline echocardiographic parameters, New York Heart Association (NYHA) class, age, gender, beta blocker use, and etiology of heart failure (HF) were analyzed for the clinical end points of the study as well as 6-month HF re-hospitalization or death.


RESULTS
The benefit of CRT over control was similar in all subgroups with respect to all clinical endpoints. However, non-ischemic HF patients had greater improvements with CRT compared to ischemic HF patients in left ventricular end diastolic volume (P < 0.001) and ejection fraction (EF) (6.7% increase vs. 3.2% [P < 0.001]). Greater improvements in EF were also seen in those patients with less severe baseline mitral regurgitation (MR) (P < 0.001). Women but not men receiving CRT were more likely to be event-free from first HF hospitalization or death compared to the control group (Hazard Ratio = 0.157).


CONCLUSIONS
The benefits of CRT with respect to EF and reverse remodeling were greater in patients with non-ischemic HF and less severe MR. Women may also derive more benefit than men with respect to the occurrence of HF hospitalization or death.
Woo
Gregory W
GW
Division of Cardiovascular Diseases, Department of Medicine, University of Florida, Gainesville, FL 32610, USA. woogw@hotmail.com
Petersen-Stejskal
Susan
S
Johnson
James W
JW
Conti
Jamie B
JB
Aranda
Juan A
JA
Curtis
Anne B
AB
D000368:Aged; D000704:Analysis of Variance; D002304:Cardiac Pacing, Artificial; D017147:Defibrillators, Implantable; D004452:Echocardiography; D004554:Electric Countershock; D005260:Female; D006333:Heart Failure / Q000503:physiopathology / Q000628:therapy*; D006801:Humans; D008297:Male; D008875:Middle Aged; D016016:Proportional Hazards Models; D011788:Quality of Life; D018709:Statistics, Nonparametric; D016019:Survival Analysis; D016896:Treatment Outcome; D018487:Ventricular Dysfunction, Left; D020257:Ventricular Remodeling / Q000502:physiology*
Circulation. 1994 Jan;89(1):68-75
8281697
Am J Cardiol. 1991 Aug 1;68(4):355-9
1858676
Am J Cardiol. 2002 Feb 1;89(3):346-50
11809441
Circulation. 2002 Mar 19;105(11):1304-10
11901040
J Am Coll Cardiol. 2002 Aug 7;40(3):536-45
12142123
Pacing Clin Electrophysiol. 2000 Nov;23(11 Pt 2):1722-5
11139909
N Engl J Med. 2002 Jun 13;346(24):1845-53
12063368
Circulation. 1997 Sep 16;96(6):1999-2008
9323092
Circulation. 2003 Apr 22;107(15):1985-90
12668512
Am J Cardiol. 1988 Jul 11;62(2):25A-30A
3389302
Circulation. 2000 Jun 13;101(23):2703-9
10851207
Circulation. 1990 Feb;81(2 Suppl):III48-53
2404638
Am J Cardiol. 1993 Sep 15;72 (9):672-6
8249843
N Engl J Med. 2004 May 20;350(21):2140-50
15152059
Pacing Clin Electrophysiol. 2003 Jan;26(1 Pt 2):175-80
12687807
Clin Cardiol. 2000 May;23 (5):355-8
10803444
J Am Coll Cardiol. 2000 Apr;35(5):1221-7
10758964
J Am Coll Cardiol. 2001 Dec;38(7):1957-65
11738300
J Am Coll Cardiol. 2003 Mar 5;41(5):765-70
12628720
Am Heart J. 1992 Apr;123(4 Pt 1):993-7
1550009
Circulation. 1997 Aug 5;96(3):827-33
9264489
J Am Coll Cardiol. 1996 Mar 15;27(4):883-93
8613619
Int J Cardiol. 1997 Jan 3;58(1):41-5
9021426
Am Heart J. 2000 Dec;140(6):862-70
11099989
Eur Heart J. 1992 Dec;13(12):1611-8
1289089
JAMA. 2003 Feb 12;289(6):730-40
12585952
Eur J Heart Fail. 2001 Aug;3(4):441-7
11511430
Am J Cardiol. 2003 Mar 15;91(6):684-8
12633798